Literature DB >> 15888509

CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers.

Marlies A van Duinen1, Koen R J Schruers, Michael Maes, Eric J L Griez.   

Abstract

The 35% CO(2) challenge is known to induce symptoms of a panic attack both in panic disorder (PD) patients and healthy volunteers. Although the challenge applies more to PD patients, studies in healthy volunteers provide the opportunity to isolate the physical symptoms from the disorder and to focus on the direct effect from the challenge on stress responsive systems. One of the main stress responsive systems is the hypothalamic-pituitary-adrenal (HPA) axis. It remains unclear whether panic symptoms are accompanied by HPA axis activation. Differences in design have hampered any comparison between studies. For example, both serum and salivary cortisol have been used to provide an index of HPA axis activation. Furthermore, indications for central HPA axis disturbance have been suggested. The current study aimed to study the HPA axis response following the induction of panic symptoms in healthy volunteers, both at the pituitary level and at the adrenal level. Furthermore, both serum and salivary cortisol levels were determined. Subjective feelings of anxiety and, correspondingly, cortisol and ACTH levels, were found to be significantly increased following the 35% CO(2) challenge. Cortisol and ACTH responses to CO(2) were also associated. A significant cortisol increase was observed in both serum and saliva samples, although these were more pronounced when considering the free fraction serum values. We conclude that the induction of panic symptoms results in HPA axis activation, both at the pituitary and adrenal level. The question remains as to whether positive responders to the 35% CO(2) inhalation (more specifically PD patients) show a more pronounced HPA axis response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888509     DOI: 10.1177/0269881105051527

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  Effect of social stress during acute nicotine abstinence.

Authors:  Margaret C Wardle; Marcus R Munafò; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2011-01-15       Impact factor: 4.530

2.  Carbon dioxide-induced anesthesia results in a rapid increase in plasma levels of vasopressin.

Authors:  Brian Reed; Jack Varon; Brian T Chait; Mary Jeanne Kreek
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

Review 3.  Sex differences in salivary cortisol in response to acute stressors among healthy participants, in recreational or pathological gamblers, and in those with posttraumatic stress disorder.

Authors:  Jason J Paris; Christine Franco; Ruthlyn Sodano; Brian Freidenberg; Elana Gordis; Drew A Anderson; John P Forsyth; Edelgard Wulfert; Cheryl A Frye
Journal:  Horm Behav       Date:  2009-06-16       Impact factor: 3.587

4.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

Review 5.  Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Authors:  R E Nordquist; T Steckler; J G Wettstein; C Mackie; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-06       Impact factor: 4.530

6.  Re-conceptualizing stress: Shifting views on the consequences of stress and its effects on stress reactivity.

Authors:  Jenny J W Liu; Kristin Vickers; Maureen Reed; Marilyn Hadad
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

7.  Maternal stress and the MPOA: Activation of CRF receptor 1 impairs maternal behavior and triggers local oxytocin release in lactating rats.

Authors:  Stefanie M Klampfl; Milena M Schramm; Barbara M Gaßner; Katharina Hübner; Audrey F Seasholtz; Paula J Brunton; Doris S Bayerl; Oliver J Bosch
Journal:  Neuropharmacology       Date:  2018-03-02       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.